Article Versions Notes

Müller M, Rösch L, Najafi S, Gatzweiler C, Ridinger J, Gerloff XF, Jones DTW, Baßler J, Kreth S, Stainczyk S, et al. Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers. 2021; 13(17):4476. https://doi.org/10.3390/cancers13174476

Müller, Michael, Lisa Rösch, Sara Najafi, Charlotte Gatzweiler, Johannes Ridinger, Xenia F. Gerloff, David T. W. Jones, Jochen Baßler, Sina Kreth, Sabine Stainczyk, and et al. 2021. "Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma" Cancers 13, no. 17: 4476. https://doi.org/10.3390/cancers13174476

Müller, M., Rösch, L., Najafi, S., Gatzweiler, C., Ridinger, J., Gerloff, X. F., Jones, D. T. W., Baßler, J., Kreth, S., Stainczyk, S., Frese, K., Meder, B., Westermann, F., Milde, T., Peterziel, H., Witt, O., & Oehme, I. (2021). Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers, 13(17), 4476. https://doi.org/10.3390/cancers13174476